Skip to main content

Table 3 Lipid modifying treatment of study population

From: First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients

 

Overall N = 712

LDL-C goal attainment N = 71

No LDL-C goal attainment N = 641

p-value

Monotherapy

476 (66.9)

43 (60.6)

433 (67.6)

0.2

Statin

465 (65.3)

43 (60.6)

422 (65.8)

0.4

Fibrate

4 (0.6)

0 (0)

4 (0.6)

1.0

Ezetimibe

7 (1.0)

0 (0)

8 (1.2)

1.0

Combination therapy

236 (33.1)

28 (39.4)

208 (32.4)

0.2

Statin + Ezetimibe

182 (25.6)

22 (31.0)

160 (25.0)

0.3

Statin + Ezetimibe + n3 fatty acids

24 (3.4)

2 (2.8)

22 (3.4)

1.0

Statin + n3 fatty acids

24 (3.4)

2 (2.8)

22 (3.4)

1.0

Other

6 (0.8)

2 (2.8)

4 (0.6)

0.1

% LDL-C reduction efficacy

   

0.5

low

42 (5.9)

4 (5.6)

38 (5.9)

 

moderate

486 (68.3)

45 (63.4)

441 (68.8)

 

high

160 (22.5)

18 (25.4)

142 (22.2)

 

very high

24 (3.4)

4 (5.6)

20 (3.1)

 
  1. Data are expressed as n (%).